Introduction {#sec1-1}
============

Iron is an essential micronutrient ([@ref1]) that can cycle reversibly between its ferrous (Fe^2+^) and ferric (Fe^3+^) oxidation states ([@ref2]). This property is essential for iron functions, but makes it very dangerous, since free iron is a powerful catalyst for hydroxyl radical formation and lipid peroxidation ([@ref3]). Iron-overload conditions cause iron deposition in different body organs including liver, which is the major site of iron storage ([@ref4]). Iron is stored in the liver as ferritin, in which iron is not available to participate in Fenton reaction and, with heavy iron loading, as hemosiderin ([@ref5]).

Evidence has shown that iron has an important role in various tissue injuries of the body involving reactive oxygen species ([@ref6]). It has been suggested that iron can exert renal toxicity ([@ref7]) and it has been implicated in renal tubular injury due to the formation of hydroxyl (•OH) radical ([@ref8]). Also, the critical role of iron in mediating tissue injury in several models of acute kidney injury induced by rhabdomyolysis ([@ref9]), cisplatin ([@ref10]), and ischemia/reperfusion ([@ref11]) is well established.

Extracts obtained from the roots and barks of various Berberis species are used as folk remedies worldwide for the treatment of various inflammatory ailments ([@ref12]). Berberine is an isoquinoline alkaloid, which could be found in the root, rhizome, and stem bark of several plant species, such as *Berberis vulgaris*. Berberine exerts a wide range of pharmacological properties, including anti-inflammatory ([@ref12]), antihypercholesterolemic ([@ref13]), antihyperlipidaemic ([@ref14]), antiemetic ([@ref15]), and antitoxic ([@ref1]). Nevertheless, the protective role of berberine against ferrous sulfate (FS)-induced hepato- and nephrotoxicity has not been investigated. Thus, the goal of the current report is to evaluate the ability of berberine in protection against FS-induced functional disorders and liver and kidney tissue damage in rats.

Materials and Methods {#sec1-2}
=====================

Experimental procedure {#sec2-1}
----------------------

Male Wistar rats (250--300 g) were purchased from Razi Institute, Shiraz, Iran. They were maintained at 25 ± 2 °C with a 12:12 hr light/dark cycle. The animals had free access to a standard pellet diet and water *ad libitum*. The Ethics committee of Shiraz University approved the study. The rats were divided into four groups (7 each): Sham (1 ml distilled water was given intraperitoneally), Ber (berberine, 10 mg/kg/day dissolved in 1 ml distilled water and given by gavage for 14 days), FS (ferrous sulfate, 30 mg/kg/day dissolved in 1 ml distilled water and given intraperitoneally (IP) for14 days), FS + Ber (ferrous sulfate, 30 mg/kg/day for 14 days; berberine, 10 mg/kg/day for 11 days from fourth day of ferrous sulfate injection). After14 days of ferrous sulfate/berberine treatment, rats were placed in metabolic cages and 24-hr urine was collected. Thereafter, rats were anesthetized with ketamine (60 mg/kg, IP) and xylazine (5 mg/kg, IP) and blood samples were obtained from heart ventricles. Then the liver and the left kidney were quickly isolated. Parts of liver and kidney were preserved for future histological examination and the rest was immediately snap-frozen in liquid nitrogen and stored at -70 °C until further use. Rats were killed by injecting an overdose of anesthetics.

Renal functional assessments {#sec2-2}
----------------------------

Urine samples were collected at the end of the 24-hr period and total volume was recorded. Urinary creatinine was measured by colorimetric methods (Prestige, Biolis24I, Japan) and used in conjunction with serum creatinine concentration and urine flow to calculate creatinine clearance (C~Cr~) as an indicator of glomerular function. Urinary Na^+^ was measured at the end of the 24-hr period and used in conjunction with serum Na^+^ to estimate the fractional excretion of Na^+^ (FE~Na~) as an indicator of tubular dysfunction.

Biochemical estimation {#sec2-3}
----------------------

Alanine aminotransferase (ALT), aspartate amino-transferase (AST), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP) activities in serum and liver tissue samples (homogenized in a citrate buffer, pH 4.8, centrifuged at 10000 × g for 15 min at 4 °C, the supernatant was removed and stored on ice) were measured by commercially available kits. Also, total protein, albumin, glucose, triglycerides, and cholesterol concentrations in serum were measured by commercially available kits.

Lipid peroxidation assay {#sec2-4}
------------------------

Malondialdehyde (MDA) levels were determined spectrophotometrically in tissue samples (homogenized in 5 ml of trichloroacetic acid per 0.1 g of tissue) ([@ref16]). Malondialdehyde reacts with thiobarbituric acid (TBA) to produce a pink color with an absorption maximum at 532 nm.

Histopathological examinations {#sec2-5}
------------------------------

Liver and kidney samples were fixed in the buffered 10 % formaldehyde. After dehydration through a graded alcohol series, the samples were cleared in xylol. Then, liver and kidney samples were embedded in paraffin and 5-μm sections were obtained using a microtome (Erma, Japan). Routine staining with Prussian blue as well as hematoxylin and eosin were done for each liver and kidney section. In a blinded fashion, each section was examined in at least 10 randomly selected non-overlapping fields under a light microscope. In each liver section, the degree of the presence of congestion and cellular degenerative changes were examined. The renal histopathology was quantified for tubular necrosis, loss of brush borders, and formation of casts and vascular congestion. The level of each pathological manifestation was graded according to the observed changes as follow: none with 0, less than 20 % with 1, 21--40 % with 2, 41--60% with 3, 61--80 % with 4, and greater than 80 % with 5. The sum of all numerical scores in each group was taken as the total histopathological score.

Statistical analysis {#sec2-6}
--------------------

Data are presented as mean±SEM. They were assessed by one-way analysis of variance followed by Tukey's *post hoc* for comparison between groups. All data analyses were performed using SPSS (ver. 22) software package (SPSS Software, Chicago, IL, USA) and significance was considered at *P*\<0.05.

Results {#sec1-3}
=======

Effect of berberine on FS-induced changes in body weight {#sec2-7}
--------------------------------------------------------

[Figure 1](#F1){ref-type="fig"} shows that body weight values of the FS group had no significant change in comparison with sham and Ber groups (*P*\<0.05). In the FS+Ber group body weight value was statistically lower in comparison with sham (*P*\<0.001) and Ber (*P*\<0.01) groups, but it showed no significant change in comparison with the FS group.

![Berberine and ferrous sulfate-induced changes in body weight. Data are the mean±SEM (n=7 in each group). \*\*\**P*\<0.001 compared with the sham group; ††*P*\<0.01 compared with the Ber group](IJBMS-21-476-g001){#F1}

Effect of berberine on FS-induced changes in hepatic functional markers {#sec2-8}
-----------------------------------------------------------------------

[Figure 2](#F2){ref-type="fig"} depicts the levels of serum hepatic markers in sham and experimental rats. In Fe-treated rats, the activities of AST, ALT, ALP, and LDH were significantly increased (*P*\<0.01, *P*\<0.05, *P*\<0.001, *P*\<0.001, respectively). Administration of berberine significantly reversed these changes (*P*\<0.01, *P*\<0.05, *P*\<0.001, and *P*\<0.001 for AST, ALT, ALP, and LDH, respectively).

![Berberine and ferrous sulfate-induced changes in hepatic enzyme activities. Data are the mean±SEM (n=7 in each group). \**P*\<0.05, \*\**P*\<0.01, and \*\*\* *P*\<0.001 compared with the sham group; † *P*\<0.05, †† *P*\<0.01, and ††† *P*\<0.001 compared with the Ber group; \#*P*\<0.05 and \#\#\# *P*\<0.001 compared with the ferrous sulfate (FS) group](IJBMS-21-476-g002){#F2}

[Table 1](#T1){ref-type="table"} shows that serum levels of total protein (*P*\<0.05), albumin (*P*\<0.01), triglycerides (*P*\<0.001, *P*\<0.01 compared with sham and Ber groups, respectively), cholesterol (*P*\<0.01), and glucose (*P*\<0.001, *P*\<0.01 compared with sham and Ber groups, respectively) in the FS group were statistically lower than those of sham and Ber groups. It also shows that serum level of total bilirubin in the FS group was statistically higher than those of sham and Ber groups (*P*\<0.001). Berberine treatment significantly reversed these changes (*P*\<0.05 for all except *P*\<0.001 for total bilirubin, *P* \<0.01 for triglyceride and cholesterol).

###### 

Effect of berberine on FS-induced changes in the levels of rat serum biochemical parameters

  Groups                  Sham            Ber             FS                                                                                 FS + Ber
  ----------------------- --------------- --------------- ---------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Total bilirubin (U/l)   0.62±0.11       0.60±0.11       3.28±0.38[\*\*\*](#t1f3){ref-type="table-fn"}[†††](#t1f6){ref-type="table-fn"}     2.25±0.30[\*\*\*](#t1f3){ref-type="table-fn"}[†††](#t1f6){ref-type="table-fn"}[♯♯♯](#t1f9){ref-type="table-fn"}
  Total protein (mg/dl)   6.58±0.44       6.72±0.29       5.24±0.29[\*](#t1f1){ref-type="table-fn"}[†](#t1f4){ref-type="table-fn"}           6.40±0.14[♯](#t1f7){ref-type="table-fn"}
  Albumin (mg/dl)         4.34±0.22       4.11±0.30       2.74±0.18[\*\*](#t1f2){ref-type="table-fn"}[††](#t1f5){ref-type="table-fn"}        3.44±0.23[♯](#t1f7){ref-type="table-fn"}
  Triglyceride (mg/dl)    75.28 ± 6.09    61.85 ± 7.10    31.42 ± 4.94[\*\*\*](#t1f3){ref-type="table-fn"}[††](#t1f5){ref-type="table-fn"}   67.71 ± 4.67[♯♯](#t1f8){ref-type="table-fn"}
  Cholestrol (mg/dl)      47.42 ± 2.99    47.00 ± 2.74    31.28 ± 1.74[\*\*](#t1f2){ref-type="table-fn"}[††](#t1f5){ref-type="table-fn"}     46.14 ± 4.63[♯](#t1f7){ref-type="table-fn"}
  Glucose (mg/dl)         127.71 ± 9.30   132.42 ± 8.93   68.14 ± 3.63[\*\*](#t1f2){ref-type="table-fn"}[†††](#t1f6){ref-type="table-fn"}    126.28 ± 13.56[♯♯](#t1f8){ref-type="table-fn"}

*P*\<0.05,

*P*\<0.01, and

*P*\<0.001 as compared to the sham group;

*P*\<0.05,

*P*\<0.01, and

*P*\<0.001 as compared to the Ber group;

*P*\<0.05,

*P*\<0.01, and

*P*\<0.00, as compared to the FS group

Ber: berberine; FS: ferrous sulfate

[Table 2](#T2){ref-type="table"} shows that AST, ALT, ALP, and LDH levels of liver tissue in the FS group were statistically higher than those of sham and Ber groups (*P*\<0.01, *P*\<0.05, *P*\<0.001, and *P*\<0.001, respectively). Berberine treatment reduced the levels of AST, ALT, ALP, and LDH in FS + Ber in comparison to the FS group (*P*\<0.05, *P*\<0.05, *P*\<0.001, and *P*\<0.001, respectively).

###### 

Effect of berberine on FS-induced changes in the activities of hepatic and lipid peroxidation markers in liver tissue homogenates in experimental groups (each n=7)

  Groups               Sham             Ber               FS                                                                                      FS + Ber
  -------------------- ---------------- ----------------- --------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  AST (U/l)            761.14 ± 31.67   715.00± 67.00     1818.28 ± 41.94[\*\*](#t2f2){ref-type="table-fn"}[††](#t2f5){ref-type="table-fn"}       1584.57± 97.31[♯](#t2f7){ref-type="table-fn"}
  ALT (U/l)            665.71± 35.96    687.00 ± 16.93    1797.00 ± 118.99[\*](#t2f1){ref-type="table-fn"}[†](#t2f4){ref-type="table-fn"}         1483.42±39.39[♯](#t2f7){ref-type="table-fn"}
  ALP (U/l)            685.85 ± 40.71   678.28 ± 51.15    1532.00 ± 36.62[\*\*\*](#t2f3){ref-type="table-fn"}[†††](#t2f6){ref-type="table-fn"}    1387.00±59.20[\*](#t2f1){ref-type="table-fn"}[†](#t2f4){ref-type="table-fn"}[♯♯♯](#t2f8){ref-type="table-fn"}
  LDH (U/l)            692.42 ± 48.81   693.001 ± 43.08   3243.71 ± 270.07[\*\*\*](#t2f3){ref-type="table-fn"}[†††](#t2f6){ref-type="table-fn"}   2363 ± 195.65[♯♯♯](#t2f8){ref-type="table-fn"}
  MDA (mol/g tissue)   0.42 ± 0.04      0.55 ± 0.09       1.40 ± 0.20[\*\*\*](#t2f3){ref-type="table-fn"}[†††](#t2f3){ref-type="table-fn"}        0.84 ± 0.10[♯♯♯](#t2f8){ref-type="table-fn"}

*P*\<0.05,

*P*\<0.01, and

*P*\<0.001 as compared to the sham group;

*P*\<0.05,

*P*\<0.01, and

*P*\<0.001 as compared to the Ber group;

*P*\<0.05,

\#\#*P*\<0.01, and

*P*\<0.001, as compared to the ferrous sulfate (FS) group

Effect of berberine on FS-induced changes in renal function parameters {#sec2-9}
----------------------------------------------------------------------

In Fe-treated rats, renal functional markers such as creatinine, urea nitrogen ([Table 3](#T3){ref-type="table"}), and fractional Na^+^-excretion (FE~Na~) ([Figure 3](#F3){ref-type="fig"}) were significantly increased (*P*\<0.01, *P*\<0.001, and *P*\<0.01, respectively), while creatinine clearance was significantly (*P*\<0.05) decreased ([Figure 3](#F3){ref-type="fig"}). Administration of berberine significantly reversed these changes (*P*\<0.001, *P*\<0.01, *P*\<0.001, and *P*\<0.01 for creatinine, urea nitrogen, fractional Na^+^-excretion, and creatinine clearance, respectively).

###### 

Effect of berberine (Ber) on the levels of renal function parameters and lipid peroxidation marker in experimental groups (n=7)

  Groups                  Sham           Ber            FS                                                                                 FS + Ber
  ----------------------- -------------- -------------- ---------------------------------------------------------------------------------- ----------------------------------------------
  Creatinine (mg/dl)      0.45± 0.02     0.47± 0.01     0.78 ± 0.05[\*\*\*](#t3f2){ref-type="table-fn"}[†††](#t3f4){ref-type="table-fn"}   0.52 ± 0.04[♯♯♯](#t3f7){ref-type="table-fn"}
  Urea nitrogen (mg/dl)   25.42 ± 2.23   26.28 ± 2.69   36.42 ± 2.05[\*\*](#t3f1){ref-type="table-fn"}[††](#t3f3){ref-type="table-fn"}     26.42 ± 1.25[♯♯](#t3f6){ref-type="table-fn"}
  MDA (mol/g tissue)      0.42 ± 0.04    0.55 ± 0.10    1.25 ± 0.21[\*\*\*](#t3f2){ref-type="table-fn"}[††](#t3f3){ref-type="table-fn"}    0.75 ± 0.07[♯](#t3f5){ref-type="table-fn"}

\**P*\<0.05,

*P*\<0.01,

*P*\<0.001 vs sham group;

†*P*\<0.05,

*P*\<0.01,

*P*\<0.001 vs Ber group;

*P*\<0.05,

*P*\<0.01,

*P*\<0.00, vs FS group

![Berberine and ferrous sulfate-induced changes in renal function parameters (CCr and FENa). Data are the mean±SEM (n=7 in each group). \*\*\* *P*\<0.001 compared with the sham group; † *P*\<0.05 and ††† *P*\<0.001 compared with the Ber group; \#\# *P*\<0.01 and \#\#\# *P*\<0.001 compared with the FS group](IJBMS-21-476-g003){#F3}

Effect of berberine on FS-induced oxidative stress in the liver and kidney {#sec2-10}
--------------------------------------------------------------------------

Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} show that ferrous sulfate treatment resulted in significant increases in MDA contents of the liver (*P*\<0.001) and kidney (*P*\<0.001) compared with the sham and Ber groups. Berberine treatment reduced the levels of MDA contents of the liver (*P*\<0.001) and kidney (*P*\<0.05) in FS + Ber in comparison to the FS group.

Effect of berberine on FS-induced histological damages in the liver and kidney {#sec2-11}
------------------------------------------------------------------------------

Results of the histological studies of the liver were in agreement with the measured activities of hepatic enzymes. There were no abnormalities or histological changes in the livers of sham and Ber groups (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). In the FS group ([Figure 3](#F3){ref-type="fig"}), iron deposition which indicates accumulation of iron (grade 2) was observed. In the FS + Ber group ([Figure 3](#F3){ref-type="fig"}) less iron deposition (grade 1) was noticed in comparison with the FS group. In the FS group the most prominent lesions were hepatocellular ballooning (grade 2, [Figure 5a](#F5){ref-type="fig"}), apoptosis of the hepatic cells (grade 2, [Figure 5b](#F5){ref-type="fig"}), infiltration of inflammatory cells in the portal space (grade 3, [Figure 5c](#F5){ref-type="fig"}), and vacuolization of the hepatocyte cytoplasm (grade 2, [Figure 5d](#F5){ref-type="fig"}). In the FS + Ber group, less intense lesions were noticed in comparison with the FS group (Figures [5e](#F5){ref-type="fig"} and [5f](#F5){ref-type="fig"}).

![Representative light microphotographs of the livers. Prussian blue-stained sections were evaluated by light microscopy. The histological changes observed included iron deposition](IJBMS-21-476-g004){#F4}

![Representative light microphotographs of the livers. Haematoxylin and eosin-stained sections were evaluated by light microscopy. The histological changes observed included apoptosis (a), swelling (b), vacuolization (c), and inflammatory cell infiltration (d)](IJBMS-21-476-g005){#F5}

Renal sections from the sham (Figures [6a~1~](#F6){ref-type="fig"}, [6a~2~](#F6){ref-type="fig"}, [6a~3~](#F6){ref-type="fig"}, and [6a~4~](#F6){ref-type="fig"}) and Ber groups (Figures [6b~1~](#F6){ref-type="fig"}, [6b~2~](#F6){ref-type="fig"}, [6b~3~](#F6){ref-type="fig"}, and [6b~4~](#F6){ref-type="fig"}) exhibited only minimal or no changes. In the FS group, iron deposition (grade 2) was observed in the cortex ([Figure 6c~1~](#F6){ref-type="fig"}) and medulla ([Figure 6c~2~](#F6){ref-type="fig"}). However, in the FS + Ber group ([Figures 6d~1~](#F6){ref-type="fig"} and [6d~2~](#F6){ref-type="fig"}) less iron deposition (grade 1) was noticed in comparison with the FS group. Furthermore, in the FS group, there was congestion (grade 2) in glomerular capillaries ([Figure 6c~3~](#F6){ref-type="fig"}) and medullary vessels ([Figure 6c~4~](#F6){ref-type="fig"}). However, in the FS + Ber group (Figures [6d~3~](#F6){ref-type="fig"} and [6d~4~](#F6){ref-type="fig"}) less congestion (grade 1) was observed in comparison with the FS group. The sum of histopathological grades, marking the changes described above, is mentioned in [Table 4](#T4){ref-type="table"}.

![Representative light microphotographs of the kidneys. Prussian blue- and hematoxylin & eosin-stained sections were evaluated by light microscopy. The histological changes observed included iron deposition in the cytoplasm of: cortical (c1, d1) and medullary (c2, d2) tubular cells, Prussian blue staining; glomerular capillary congestion (c3, d3) and medullary vascular congestion (c4, d4), haematoxylin-eosin staining](IJBMS-21-476-g006){#F6}

###### 

Total histopathological score in Sham, berberine (Ber), ferrous sulfate FS, and FS + Ber groups (n=7) at the end of the experiment

  Experimental groups   Liver                                              Kidney
  --------------------- -------------------------------------------------- -------------------------------------------------
  Sham                  0.0 ± 0.00                                         0.0 ± 0.00
  Ber                   0.0 ± 0.00                                         0.0 ± 0.00
  FS                    11.25 ± 0.55[\*\*\*](#t4f1){ref-type="table-fn"}   7.62 ± 0.37[\*\*\*](#t4f1){ref-type="table-fn"}
  FS + Ber              4.25 ± 0.36[^†††^](#t4f2){ref-type="table-fn"}     3.75 ± 0.25[^†††^](#t4f2){ref-type="table-fn"}

Values (sum of histopathological scores in each group) are expressed as mean±xsSEM

*P*\<0.001 as compared to the Sham and Ber groups

*P*\<0.001 as compared to the FS groups

Discussion {#sec1-4}
==========

The present study demonstrated that ferrous sulfate (FS) leads to functional disorders and histological damages to the liver and kidney. Our findings suggest that berberine treatment attenuates FS-induced liver and kidney functional injury and MDA levels in hepatic and renal tissues compared to the FS group.

It has been suggested that chronic deposition of excess iron in hepatic parenchymal cells can lead to hepatic injury ([@ref5]). In the present study, changes in AST, ALT, ALP, and LDH in serum and liver tissue following FS administration are indicators of liver damage. Induction of oxidative stress and the increased production of reactive oxygen species, as a result of excessive iron deposition in the liver, are thought to play key roles in triggering the damage ([@ref17]). In the FS group, administration of berberine (10 mg/kg/day for 14 days) significantly protected hepatocytes against toxic effects of iron, as shown by improvement in histology and prevention of increase in plasma AST, ALT, ALP, and LDH levels and liver lipid peroxidation. In this regard, the membrane protective effect of berberine has already been reported ([@ref18]).

One of the most important functions of the liver is protein synthesis. From the results obtained, there was a significant decrease in total protein and albumin levels in the FS group compared to that of the sham group. In agreement with our results, it has been shown that total protein level is decreased in FS-induced hepatotoxicity ([@ref17], [@ref19]). The berberine-induced rise in the levels of total protein and albumin demonstrated that berberine could improve liver function.

In this work, ferrous sulfate treatment resulted in decreased serum glucose concentration. The liver releases glucose both by glycogenolysis and gluconeogenesis ([@ref20]). It has been suggested that imperfect energy-linked mitochondrial function impairs gluconeogenesis, and depletion of hepatic glycogen stores following uncoupling of oxidative phosphorylation leads to hypoglycemia ([@ref21]). Berberine treatment significantly inversed the ferrous sulfate induced peroxidative damage in the liver as evidenced by the lower levels of MDA, probably due to the antioxidative effect of berberine. Besides, berberine raised glucose concentration to the normal level due to its ability to reduce lipid peroxidation. In this regard, earlier experimental findings have suggested that berberine induces glycolysis as a consequence of inhibition of glucose oxidation in mitochondria ([@ref22]). Protecting the ability of berberine against Fe^2+^-induced lipid peroxidation has been already shown ([@ref23]). Light microscopy for experimental groups showed that accumulation of iron in the liver was effectively reduced by berberine, which reveals that berberine chelates the iron ([@ref18]). It is well noticed that berberine possesses antioxidant action ([@ref18]), which can scavenge the excess iron in biological systems.

Oxidative stress is frequently stated to be a central mechanism of hepatocellular injury. In the present study, other considerable pathological features of FS-induced hepatotoxicity were leukocyte infiltration and apoptosis. It might be due to the formation of ROS due to iron-induced oxidative stress ([@ref24]). Administration of berberine reduced the histological alterations induced by ferrous sulfate and restored normal physiological functions. This is in accordance with the result of Ghareeb *et al*. (2015) who found that berberine attenuated inflammatory cell infiltrations induced by CCL~4~ in the liver ([@ref25]).

Light microscopy for the FS group showed hepatocyte ballooning and cytoplasmic vacuolization. High dose of ferrous sulfate led to increased levels of serum concentrations of cholesterol and TG in the FS group. The Fe-induced rise of cholesterol in serum may be due to changes in the gene expression of hepatic enzymes mainly HMG-COA reductase as was suggested by others ([@ref26]). Berberine attenuated the increased blood levels of these lipids in the FS+Ber group. Taken together, the therapeutic effect of berberine against hyperlipidemia, observed in this study, is probably due to the combined effect of its inhibitory activity of HMG-CoA reductase ([@ref25]) and its antioxidant capacity ([@ref18]). Besides, Brusq *et al*. have demonstrated that berberine inhibits cholesterol ([@ref27], [@ref28]) and TG ([@ref28]) synthesis in hepatic cells.

Histopathological evaluations of the FS group kidneys showed mild congestion of glomerular capillaries and medullary vessels. Besides, moderate iron deposition in the cytoplasm of tubular cells in the FS group was the basis for cellular damage. The prolonged keeping of Fe in the tissues elevates oxidative stress that ends in pathological changes in the kidney ([@ref1]). Administration of berberine reduced the renal histological alterations induced by ferrous sulfate.

It is well known that oxidative stress plays a major role in the renal structural and functional deterioration by altering biochemical indicators. In this study, FS-induced nephrotoxicity was manifested by elevated serum creatinine and BUN levels ([Table 3](#T3){ref-type="table"}). These results are in accordance with the findings of Pari *et al*. (2015) in male rats ([@ref29]). It is recognized that elevated blood urea is correlated with increased protein catabolism in mammals ([@ref30]). Our results show that serum concentrations of total protein were decreased in the FS group ([Table 1](#T1){ref-type="table"}). Also, the increase in serum urea and creatinine concentrations as well as FE~Na~ in this work may be the result of kidney dysfunction. In our model of FS-induced nephrotoxicity, berberine showed remarkable useful effects, with the almost complete restoration of C~Cr~ and FE~Na~ to normal levels. This prevention of the C~Cr~ decrease and FE~Na~ increase was along with fewer histological damages. Berberine administration significantly inversed the ferrous sulfate induced peroxidative damage in the kidney which is evident from the lowered levels of MDA, probably due to its antioxidant feature ([@ref1], [@ref31]). In this regard, the nephroprotective effect of berberine against renal damage induced by cisplatin ([@ref32]) and gentamicin ([@ref33]) through its antioxidant, anti-inflammatory, and anti-apoptotic properties is well documented.

Conclussion {#sec1-5}
===========

In summary, this study demonstrates for the first time that berberine has potent protective effects against iron-induced hepato- and nephrotoxicity. Here we demonstrate that berberine administration attenuated serum and tissue hepatic markers, bilirubin, creatinine, BUN, lipid peroxidation marker, iron deposition, renal functional disorders, and renal histological damages, and normalized the hepatic cells' architecture. Berberine exerts its hepato- and nephroprotective effects via its antioxidant potential by scavenging the free radicals and chelating iron through binding to iron and reducing the concentration of the catalyzing iron in lipid peroxidation. Since berberine itself did not exert harmful effects in normal rats, it should be considered as a hepato- and nephroprotective agent in iron-induced hepato- and nephrotoxicity. However, clinical experiments to acknowledge the efficacy of berberine treatment in patients are necessary.
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